Effect of the combination of uridine nucleotides, folic acid and vitamin B12 on the clinical expression of peripheral neuropathies

What Was Tested

Researchers studied Cyanocobalamin (Vitamin B12) in this clinical trial publication.

The pathophysiology of PN is characterized by lesions of myelin-producing Schwann cells in peripheral nerves.

Regeneration/protection of the myelin sheath after a nerve lesion is a fundamental element of repair in PN.

Who Took Part

According to the abstract, 212 patients were involved.

By PubMed's age tags, the people studied were young adults, adults, middle-aged adults, older adults and people over 80, both men and women.

The researchers performed an exploratory, open-label, multicenter, study of 212 patients followed for 2 months.

How the Study Was Run

The researchers set it up as a open-label and multicenter study.

Everyone knew when Cyanocobalamin (Vitamin B12) was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

More than one site took part, so the patients came from several places.

The methods mention a period of 2 months.

Pain was assessed using the painDETECT questionnaire (PDQ).

What Was Measured

PubMed files the paper under topics including Analgesics, Folic Acid, Pain Management, Pain Measurement, Peripheral Nervous System Diseases, Primary Health Care and Uracil Nucleotides.

Author keywords: neuropathic pain, peripheral neuropathy and uridine monophosphate.

What This Means in Plain Language

The paper is an open-label and multicenter study of Cyanocobalamin (Vitamin B12) in 212 patients over 2 months.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2014 (Pain management), a journal based in England.

More context: the Cyanocobalamin (Vitamin B12) compound page, all human trials.